Steroid receptors and clinical outcome in patients with adenocarcinoma of the endometrium

doi:10.1016/0002-9378(88)90075-0

American Journal of Obstetrics and Gynecology

Volume 158, Issue 4, April 1988, Pages 796-805

https://doi.org/10.1016/0002-9378(88)90075-0 Get rights and content

Abstract

Progesterone receptor content was measured in tissue samples from 175 patients with endometrial adenocarcinoma by use of the dextran-charcoal method. The estradiol receptor content was determined in 138 of these samples. Ninety-two tumors (52.6%) tested positive for progesterone receptors (50 fmol/mg cytosol protein) and 111 (80.4%) tested positive for estradiol receptors (6 fmol/mg). Median follow-up was 27.3 months (range 1 to 152 months). Progesterone receptor status correlated significantly with grade, histology, adnexal spread, age, and recurrence rate in stage I cancer. There was no correlation between progesterone receptor status and clinical stage, myometrial invasion, peritoneal cytology, retroperitoneal lymph node involvement, or spread to the cervix. Estradiol receptor status correlated with adnexal spread and recurrence rate. Recurrence in patients with stage I disease was significantly more common if tumors were negative for progesterone receptor (16 of 43, 37.2%) than if they were positive (four of 57, 7%; p < 0.001). Recurrence was also more common if tumors were negative for estradiol receptor (seven of 17, 41.2%) than if they were positive (eight of 63, 12.7%; p = 0.02). In recurrent or advanced disease, response to progestin was independent of estradiol receptor content, but tumors positive for progesterone receptors responded significantly more often than those lacking progesterone receptors. Overall survival was superior for patients with progesterone receptor-positive tumors (p = 0.001). Although survival in clinical stages I and II was also superior in patients with lesions positive for progesterone receptors (p = 0.13), there was no statistical difference in survival between patients with progesterone receptor-positive or -negative cancers and surgical stages I and II disease (p = 0.12). Estradiol receptor status had no apparent correlation with survival.

References (18)

PCM Young et al.
Progesterone binding in human endometrial adenocarcinomas
Am J Obstet Gynecol
(1976)
JD Martin et al.
The effect of estrogen receptor status on survival in patients with endometrial cancer
Am J Obstet Gynecol
(1983)
CE Ehrlich et al.
Cytoplasmic progesterone and estradiol receptors in normal, hyperplastic, and carcinomatous endometria. Therapeutic implications
Am J Obstet Gynecol
(1981)
MA Quinn et al.
Endometrial carcinoma: Steroid receptors and response to medroxyprogesterone acetate
Gynecol Oncol
(1985)
WT Creasman et al.
Influence of cytoplasmic steroid receptor content on prognosis of early stage endometrial carcinoma
Am J Obstet Gynecol
(1985)
WL McGuire et al.
Role of steroid hormone receptors as prognostic factors in primary breast cancer
Natl Cancer Inst Monogr
(1986)
RC Boronow
Endometrial cancer. The emergence of therapeutic individualization
Prog Gynecol
(1983)
PJ DiSaia et al.
Management of endometrial adenocarcinoma stage I with surgical staging followed by tailored adjuvant radiation therapy
Clin Obstet Gynecol
(1986)
TJ Benraad et al.
Do estrogen and progesterone receptors (E₂R and PR) in metastasizing endometrial cancers predict the response to gestagen therapy
Acta Obstet Gynecol Scand
(1980)

There are more references available in the full text version of this article.

Cited by (185)

Reproductive advance of fertility preservation in patients with early endometrial carcinoma or endometrial atypical hyperplasia
2022, Gynecology and Obstetrics Clinical Medicine
Endometrial cancer (EC) is the fourth common cancer in women worldwide with its incidence rising each year. 10%–15% young patients are diagnosed of EC. For patients of childbearing age with early endometrial cancer or atypical hyperplasia, it is necessary to consider surgical removal of uterus after they have given birth. It is a big challenge for reproductive doctors and oncologists to help such patients get pregnant safely as soon as possible. In this article, we will review the latest progress in conservative treatment and candidates for fertility preservation, application of molecular detection, the fertility outcome and follow-up treatment which aims to stimulate more thinking.
Estrogen Inhibits Epithelial Progesterone Receptor–Dependent Progestin Therapy Efficacy in a Mouse Model of Cervical Cancer
2022, American Journal of Pathology
Although the uterine cervix responds to the female sex hormone change, the role of progesterone in cervical cancer is poorly understood. It has been shown that medroxyprogesterone acetate (MPA) regresses cervical cancer in the transgenic mouse model expressing human papillomavirus type 16 E6 and E7 oncogenes. As MPA interacts most strongly with progesterone receptor (PR), we reasoned that PR would contribute to MPA-induced regression of cervical cancer. We also hypothesized that estrogen influences the therapeutic activity of MPA because it promotes cervical cancer growth in the same mouse model. The present study showed that the deletion of Pgr in the cervical cancer cells ablated the MPA's therapeutic effect in the human papillomavirus transgenic mouse model. Additionally, estrogen attenuated cancer regression by MPA in the same model system. These observations indicate that MPA can effectively regress cervical cancer only when cancer cells express PR and estrogen levels are low. These results suggest that, if translatable, MPA should be administered when estrogen levels are low in patients with PR-positive cervical cancer.
Chinese expert consensus on fertility-preserving treatment for young women with early stage well differentiated endometrial cancer
2021, Gynecology and Obstetrics Clinical Medicine
For young women with early stage well differentiated endometrial cancer who have fertility desire, it is import to give comprehensive assessment before initiation of conservative treatment. Progestin based therapy with regular assessment of treatment efficacy can achieve a promising outcome. After complete remission patients are suggested with assisted reproductive technology or maintenance therapy depending on their immediate pregnancy plan. Hysterectomy is recommended for patients who have finished reproduction while re-treatment for recurrent cases should be carefully informed.
Endometrial cancer: A society of gynecologic oncology evidence-based review and recommendations, part II
2021, Gynecologic Oncology
Citation Excerpt :
Several authors and the SGO recommend assessment of tumor progesterone status to better identify ideal candidates for conservative treatment [52]. Though there is limited data from fertility-sparing series and reports, a historical review reported response rates to progestin therapy of 72% for progesterone-positive tumors and 12% for progesterone-negative tumors [53]. In parallel with the above work-up, the clinician and patient, in the process of shared decision making, should discuss the likelihood of attaining pregnancy, potentially with consultation from an infertility specialist.
In 2014, the Society of Gynecologic Oncology's Clinical Practice Committee published a clinical update reviewing the treatment of women with endometrial cancer. At that time, there had been significant advances in the diagnosis, work-up, surgical management, and available treatment options allowing for more optimal care of affected women.
This manuscript, Part II in a two-part series, includes specific recommendations on treatment of recurrent disease, post treatment surveillance and survivorship, considerations for younger women, and special situations. Part I covered histopathology and molecular pathology, risk factors, presentation and diagnostic approach, surgical approach and adjuvant therapy.
Medroxyprogesterone Acetate Prevention of Cervical Cancer through Progesterone Receptor in a Human Papillomavirus Transgenic Mouse Model
2019, American Journal of Pathology
Citation Excerpt :
It is intriguing that one HPVtg/Pgr−/− mouse treated with MPA had a hypoplastic epithelium without any cervical neoplastic disease (Figure 4B and Supplemental Figure S2A). Some PR-negative endometrial cancers respond to MPA therapy.39,52 These observations suggest that MPA may be useful in preventing cervical cancer through a PR-independent mechanism under conditions yet to be determined.
Cervical dysplastic lesions called cervical intraepithelial neoplasias (CINs) need be treated to prevent cervical cancer. Currently available surgical procedures are effective, but the development of noninvasive treatment is warranted. In human papillomavirus transgenic mice engineered to express human papillomavirus type 16 E6 and E7, short-term treatment with 17β-estradiol induces CINs that progress to cervical cancer if the treatment is continued. In the present study, this mouse model was used to determine whether medroxyprogesterone acetate (MPA), a progestin drug, is chemopreventive. Human papillomavirus transgenic mice bearing CIN lesions were treated with MPA plus 17β-estradiol. Unlike control mice treated with 17β-estradiol alone, cervical cancer was absent in the MPA-treated mice. This observation suggests that MPA prevented CIN from progressing to invasive cancer. MPA was associated with inhibited cell proliferation and the promotion of apoptosis in CIN lesions. Confirming the role of the progesterone receptor, the preventive effect of MPA was absent in human papillomavirus transgenic mice in which the expression of progesterone receptor was genetically ablated. These results suggest that MPA is efficient in treating progesterone receptor–positive CIN lesions. These findings provide the basis for a biomarker-driven clinical trial of the secondary prevention of cervical cancer.
Hormone-Responsive Cancers
2019, Yen & Jaffe's Reproductive Endocrinology: Physiology, Pathophysiology, and Clinical Management: Eighth Edition
This chapter is an overview on breast cancer, prostate cancer, and endometrial cancers, with an emphasis on hormone-related components. We review the epidemiology of these cancers, focusing on the hormonal risk factors. The majority of the chapter is dedicated to a review of the main biological roles of the hormone receptors, estrogen receptor, and progesterone receptor for breast cancer, and endometrial cancer and androgen receptor for prostate cancer, in tumor initiation and as targets of endocrine treatments. We also discuss in detail the types of endocrine treatments, mechanisms of resistance to endocrine treatments, and approaches to overcome resistance.

View all citing articles on Scopus

^☆: Presented at the Sixth Annual Meeting of the American Gynecological and Obstetrical Society, Phoenix, Arizona, September 10–12 1987.

View full text

Steroid receptors and clinical outcome in patients with adenocarcinoma of the endometrium☆

Abstract

Am J Obstet Gynecol

Am J Obstet Gynecol

Am J Obstet Gynecol

Gynecol Oncol

Am J Obstet Gynecol

Role of steroid hormone receptors as prognostic factors in primary breast cancer

Natl Cancer Inst Monogr

Endometrial cancer. The emergence of therapeutic individualization

Prog Gynecol

Management of endometrial adenocarcinoma stage I with surgical staging followed by tailored adjuvant radiation therapy

Clin Obstet Gynecol

Do estrogen and progesterone receptors (E2R and PR) in metastasizing endometrial cancers predict the response to gestagen therapy

Acta Obstet Gynecol Scand

Do estrogen and progesterone receptors (E₂R and PR) in metastasizing endometrial cancers predict the response to gestagen therapy